-
1 Comment
Tellgen Corporation is currently in a long term uptrend where the price is trading 29.0% above its 200 day moving average.
From a valuation standpoint, the stock is 31.9% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 12.7.
Tellgen Corporation's total revenue rose by 31.2% to $153M since the same quarter in the previous year.
Its net income has dropped by 2.7% to $42M since the same quarter in the previous year.
Finally, its free cash flow grew by 93.7% to $25M since the same quarter in the previous year.
Based on the above factors, Tellgen Corporation gets an overall score of 3/5.
| Exchange | SHE |
|---|---|
| Sector | Healthcare |
| Industry | Medical Devices |
| CurrencyCode | CNY |
| ISIN | CNE100002P42 |
| Target Price | 23 |
|---|---|
| Dividend Yield | 1.0% |
| Beta | 0.44 |
| PE Ratio | 57.54 |
| Market Cap | 2B |
Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; cardiovascular and inflammation; biochemistry kits; DNA methylation testing kits; and molecular detection of COVID-19 and others. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in 2003 and is based in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300642.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
